Brokerages on Sun Pharma Q4 results: Most stay bullish but cut target price in Rs 470-540 range
Updated : May 29, 2019 08:45 AM IST
Sun Pharma reported a 53 percent drop in its net profit to Rs 635.9 crore for the quarter ended March 2019.
Citi Research placed the highest target price on Sun Pharma at Rs 540 per share, saying that the underlying numbers and trends indicate improvement QoQ.
Morgan Stanley gave a 'sell' call with a price target of Rs 470 per share.